These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34363507)

  • 1. Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression.
    Pennybaker S; Roach BJ; Fryer SL; Badathala A; Wallace AW; Mathalon DH; Marton TF
    Psychopharmacology (Berl); 2021 Nov; 238(11):3229-3237. PubMed ID: 34363507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic and Safety Outcomes of Intravenous Ketamine for Treatment-refractory Depression in a Veteran Population: A Case Series.
    Vitek G; Langenfeld R; Walters RW; Elson A; Driscoll D; Ramaswamy S
    Mil Med; 2023 Jul; 188(7-8):e2242-e2248. PubMed ID: 36539918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
    Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
    Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of adipokines in the rapid antidepressant effects of ketamine.
    Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
    Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
    Price RB; Spotts C; Panny B; Griffo A; Degutis M; Cruz N; Bell E; Do-Nguyen K; Wallace ML; Mathew SJ; Howland RH
    Am J Psychiatry; 2022 Dec; 179(12):959-968. PubMed ID: 36128684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression.
    Shiroma PR; Albott CS; Johns B; Thuras P; Wels J; Lim KO
    Int J Neuropsychopharmacol; 2014 Nov; 17(11):1805-13. PubMed ID: 24963561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.
    Sydnor VJ; Lyall AE; Cetin-Karayumak S; Cheung JC; Felicione JM; Akeju O; Shenton ME; Deckersbach T; Ionescu DF; Pasternak O; Cusin C; Kubicki M
    Transl Psychiatry; 2020 Dec; 10(1):432. PubMed ID: 33319774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
    McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
    Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
    Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
    World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
    Nugent AC; Diazgranados N; Carlson PJ; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Drevets WC; Zarate CA
    Bipolar Disord; 2014 Mar; 16(2):119-28. PubMed ID: 24103187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.
    Gilbert JR; Zarate CA
    Pharmacol Biochem Behav; 2020 Feb; 189():172856. PubMed ID: 31958471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
    Hosanagar A; Schmale A; LeBlanc A
    J Affect Disord; 2021 Mar; 282():252-254. PubMed ID: 33418374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.